Bibliografía del artículo
1) Castillo J, Munoz P, Guitera V, et al.: Epidemiology of chronic daily headache in the general population. Headache 1999, 39:190–196.
2) Scher AI, Stewart WF, Liberman J, et al.: Prevalence of frequent headache in a population sample. Headache 1998, 38:497–506.
3) Silberstein SD, Lipton RB, Sliwinski M. Classification of daily and near-daily headache: field trial of revised IHS criteria. Neurology 1996; 47:871-875.
4) Mathew NT. Transformed migraine. Cephalalgia. 1993;13(Suppl. 12):78-83.
5) Mathew NT, Stubits E, Nigam MP. Transformation of episodic migraine into daily headache:Analysis of factors. Headache. 1982;22:66-68.
6) Mathew NT, Reuveni U, Perez F. Transformed or evolutive migraine. Headache. 1987;27:102-106.
7) Silberstein SD, Lipton RB, Solomon S, Mathew NT. Classification of daily and near-daily headaches: Proposed revisions to the IHS criteria. Headache. 1994;34:1-7.
8) Silberstein SD, Lipton RB, Sliwinski M. Classification of daily and near-daily headaches: Field trial of revised IHS criteria. Neurology. 1996;47:871-875.
9) Manzoni GC, Granilla F, Sandrini G, Cavallini A, Zanferrari C, Nappi G. Classification of chronic daily headache by International Headache Society criteria: Limits of new proposal. Cephalalgia. 1995;15:37-43.
10) Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders. Cephalalgia. 2004; 24:1-160.
11) Olesen J. International Classification of Headache Disorders, 2nd edn (ICHD-2): Current status and future revisions. Cephalalgia. 2006;26:1409-1410.
12) Olesen J. New plans for headache classification: ICHD-3. Cephalalgia 2011 31: 4.
13) Olesen J. Bousser M-G, Diener H-C, et al. New appendix criteria open for a broader concept of chronic migraine. Cephalalgia 2006; 26: 742–746.
14) Manack A, Turkel C, Silberstein S. The Evolution of Chronic Migraine: Classification and Nomenclature. Headache 2009; 49:1206-1213.
15) Welch KMA, Nagesh V, Aurora SK, Gelman N. Periaqueductal gray matter dysfunction in migraine: cause or the burden of the illness? Headache. 2001; 42:629-637.
16) Welch KMA, Nagesh V, Aurora SK, Gelman N. Periaqueductal gray matter dysfunction in migraine: cause or the burden of the illness? Headache. 2001; 42:629-637.
17) Borkum JM. Chronic Headaches and the Neurobiology of SomatizationCurr Pain Headache Rep (2010) 14:55–61.
18) Schweinhardt P, Kuchinad A, Pukall CF, Bushnell MC: Increased gray matter density in young women with chronic vulvar pain. Pain 2008, 140:411–419.
19) Schmidt-Wilcke T, Leinisch E, Gänßbauer S, et al.: Affective components and intensity of pain correlate with structural differences in gray matter in chronic back pain patients. Pain 2006, 125:89–97.
20) Bigal ME, Lipton RB: What predicts the change from episodic to chronic migraine? Curr Opin Neurol 2009, 22:269–276.
21) Vikelis M, Mitsikostas DD: The role of glutamate and its receptors in migraine. CNS Neurol Disord Drug Targets 2007, 6:251–257.
22) Silberstein SD, Lipton RB, Dodick DW: Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. Headache 2007, 47:170–180.
23) Young WB, Mateos V, Ashkenazi A: Occipital nerve block rapidly eliminates allodynia far from the site of headache: a case report. Cephalalgia 2004, 24:906–907.
24) Matharu MS, Bartsch T, Ward N, et al.: Central neuromodulation in chronic migraine patients with suboccipital stimulators: a PET study. Brain 2004, 127:220–230.
25) Goadsby PJ, Bartsch T, Dodick DW: Occipital nerve stimulation for headache: mechanisms and efficacy. Headache 2008, 48:313–318.
26) Baskin SM, Lipchik GL, Smitherman TA. Mood and Anxiety Disorders in Chronic Headache. Headache 2006;46(Suppl 3):S76-S87.
27) Lipchik GL, Penzien DB. Psychiatric comorbidities in patiens with headache. Semin Pain Med. 2004;2:93-105.
28) Lipchik GL, Penzien DB. Psychiatric comorbidities in patiens with headache. Semin Pain Med. 2004;2:93-105.
29) Merikangas KR, Angst J, Isler H. Migraine and psychopathology. Arch Gen Psychiatry. 1990;47:849-853.
30) Lake AE, Rains JC, Penziens DB, Lipchik GL. Headache and psychiatric comorbidity: Historical context, clinical implications, and research relevante. Headache. 2005;45:493-506.
31) Radat F, Swendsen J. Psychiatric comorbidity in migrain: A review. Cephalalgia. 2004;25:165-178.
32) Natesh S, Rajashekhara SK, Rao ASD, Shetty B. Topiramate-induced angle closure with acute myopia, macular striae. Oman J Ophthalmol. 2010 Jan–Apr; 3(1): 26–28.
33) Akbarian MA, Mehrpour M. A Case report on toriramate induced myopia. Ir j pharma and therap.2004;3:66–7.
34) Spaccapelo L, Leschiutta S, Aurea C, Ferrari A. Topiramate-associated acute glaucoma in a migraine patient receiving concomitant citalopram therapy: A case-report. Cases J. 2009;2:87.[PMCID: PMC2637258] [PubMed: 19171058].
35) Fraunfelder FW, Fraunfelder FT, Keates EU. Topiramate-associated acute, bilateral, secondary angle-closure glaucoma. Ophthalmology. 2004;111:109–11. [PubMed: 14711721].
36) Newman LC, Broner SW, Lay CL. Reversible anorgasmia with topiramate therapy for migraine. Neurology 2005;65;1333-1334.
37) Holtkamp M, Weissinger F, Meierkord H. Erectile dysfunction with topiramate. Epilepsia 2005;46:166–167.
38) Tilz C, Wang-Tilz Y, Jünemann A, Stefan H, Michelson G. Visual field defect during therapy with valproic-acid. Eur J Neurol 2007;14:929–32.
39) Olerud B, Gustavasson CL. Nadolol and propanolol in migraine management. Headache 1986;26:490–493.
40) Stein DJ, Hollander E. Sexual dysfunction associated with the drug treatment of psychiatric disorders: incidence and treatment. CNS Drugs 1994;2:78–86.
41) Silberstein SD. Preventive headache treatment. Cephalalgia 1997;17:67–72.
42) Vargas BB. Chronic Migraine: Current Pathophysiologic Concepts as Targets for Treatment. Current Pain and Headache Reports 2009, 13:64–66.
43) Johannessen Landmark C. Antiepileptic drugs in non-epilepsy disorders: relations between mechanisms of action and clinical efficacy. CNS Drugs 2008;22:27-47.
44) Ashkenazi A, Benlifer A, Korenblit J, et al. Zonisamide for migraine prophylaxis in refractory patients. Cephalalgia 2006;26:1199-1202.
45) Peres MF, Zukerman E, Senne Soares CA, et al. Cerebrospinal fluid glutamate levels in chronic migraine. Cephalalgia 2004;24:735-739.
46) Luo ZD, Chaplan SR, Higuera ES, et al. Upregulation of dorsal root ganglion alpha-2 delta calcium channel subunit and its correlation with allodynia in spinal nerve injured rats. J Neurosci 2001;21:1868-1875.
47) Wang H, Bolognese J, Calder N, et al. Effect of morphine and pregabalin compared with diphenhydramine hydrochloride and placebo on hyperalgesia and allodynia induced by intradermal capsaicin in healthy male subjects. J Pain 2008;9(12):1088-1095.
48) Fehrenbacher JC, Taylor CP, Vasko MR. Pregabalin and gabapentin reduce release of substance P and CGRP from rat spinal tissues only after inflammation or activation of protein kinase C. Pain 2003;105:133-141.
49) Calandre EP, Garcia-Leiva JM, Rico-Villademoros F, et al. Pregabalin in the treatment of chronic migraine: an open-label study. Clin Neuropharmacol 2009;33:35-39.
50) Rizzato B, Leone G, Misaggi G, Zivi I, Diomedi M. Efficacy and Tolerability of Pregabalin Versus Topiramate in the Prophylaxis of Chronic Daily Headache With Analgesic Overuse: An Open-Label Prospective Study Clin Neuropharm 2011;34: 74-78.
51) Burstein R. Deconstructing migraine headache into peripheral and central sensitization. Pain 2001;89:107-110.
52) Goadsby PJ, Dodick D, Mitsias P, Khan K, Khan A, Brewer AR et al. ONSTIM: occipital nerve stimulation for the treatment of chronic migraine. Eur J Neurol 2005; 12 (Suppl. 2):198.
53) Franzini A, Ferroli P, Leone M, Broggi G. Stimulation of the posterior hypothalamus for treatment of chronic intractable cluster headaches. The first reported series. Neurosurgery 2003 52:1095-101.
54) Dodick DW, Trentman T, Zimmerman R, Eross EJ. Occipital nerve stimulation for intractable chronic primary headache disorders. Cephalagia 2003; 23:701.